Ottimo Pharma is developing first-in-class, one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of people living with cancer.

Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors 10 April 2025 - Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer, today announces the appointment of Robert Dansey, M.D., a prominent leader in oncology research and drug development, to its board of directors.
Ottimo Pharma Strengthens Leadership Team with Senior Appointments 25 February 2025 - Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of patients living with cancer, today announces the appointment of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences, who will be leading Ottimo's preclinical programs and translational strategy, and Katherine Bell-McGuinn as Senior Vice President of Clinical Development, leading Ottimo’s clinical development strategy and execution.